Cepheid
Danaher Q4 Revenues Rise 3 Percent Despite Difficulties in China
The firm's Life Sciences segment saw 8 percent growth year over year, while the Diagnostics sector rose 3 percent in the quarter.
New Products Posted to GenomeWeb: Foundation Medicine, Cepheid, Thermo Fisher, Olink, More
New products and services posted to GenomeWeb for the week of Nov. 14, 2022
Cepheid Nabs CE Mark for Group B Strep Test
The PCR-based Xpert Xpress GBS test can help screen pregnant women for Streptococcus infections that can lead to early-onset neonatal sepsis.
Danaher Q3 Revenues Rise 6 Percent as Businesses Step Back From COVID-19 Products
Life sciences revenues were up 4 percent, diagnostics revenues grew 10 percent, and environmental and applied solutions revenues increased 5 percent.
A wall of silence surrounds the fate of the point-of-care diagnostics instrument, and the company will neither confirm nor deny whether Omni has been shelved.
Apr 25, 2022
Jan 27, 2022
Danaher Q4 Revenues Rise 21 Percent
Oct 21, 2021
Jul 30, 2021
Cepheid Gets $28M From BARDA for SARS-CoV-2 Tests
Jul 29, 2021
Cepheid Nabs CE Mark for PCR-Based HIV-1 Tests
Apr 29, 2021
Apr 22, 2021
Apr 22, 2021
Danaher Q1 Revenues Up 58 Percent
Jan 28, 2021